Buflomedil

Buflomedil
Names
Preferred IUPAC name
4-(Pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.054.393
Edit this at Wikidata
PubChem CID
UNII
InChI
  • InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3 checkY
    Key: OWYLAEYXIQKAOL-UHFFFAOYSA-N checkY
  • InChI=1/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3
    Key: OWYLAEYXIQKAOL-UHFFFAOYAG
SMILES
  • O=C(c1c(OC)cc(OC)cc1OC)CCCN2CCCC2
Properties
Chemical formula
 C17H25NO4
Molar mass 307.38 g/mol
Pharmacology
C04AX20 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)
Infobox references

Buflomedil, sold under the brand name Loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States.

Toxicity

This drug has been suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity.[1][2] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.[3]

Various adverse effects have been reported to the FDA.[4]

References



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.